Cargando…
Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, being responsible for 6% of all cancer-related deaths. Surgical resection offers the only chance of cure, but only 15 to 20 percent of cases are potentially resectable at presentation. In recent years,...
Autores principales: | Bittoni, Alessandro, Santoni, Matteo, Lanese, Andrea, Pellei, Chiara, Andrikou, Kalliopi, Stefano, Cascinu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101999/ https://www.ncbi.nlm.nih.gov/pubmed/25101123 http://dx.doi.org/10.1155/2014/183852 |
Ejemplares similares
-
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016) -
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer
por: Bittoni, Alessandro, et al.
Publicado: (2021) -
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016) -
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019) -
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)